Literature DB >> 23682072

Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.

Dongxiao Sun1, Nathan R Jones, Andrea Manni, Philip Lazarus.   

Abstract

Raloxifene is a second-generation selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the prevention of breast cancer in postmenopausal women. Raloxifene is extensively metabolized by glucuronidation to form raloxifene-6-glucuronide (ral-6-Gluc) and raloxifene-4'-glucuronide (ral-4'-Gluc). The goal of the present study was to determine whether functional polymorphisms in active UGTs could play a role in altered raloxifene glucuronidation in vivo. Using homogenates from HEK293 UGT-overexpressing cell lines, raloxifene was shown to be glucuronidated primarily by the hepatic UGTs 1A1 and 1A9 and the extra-hepatic UGTs 1A8 and 1A10; no detectable raloxifene glucuronidation activity was found for UGT2B enzymes. Functional UGT1A1 transcriptional promoter genotypes were significantly (Ptrend = 0.005) associated with ral-6-Gluc formation in human liver microsomes, and, consistent with the decreased raloxifene glucuronidation activities observed in vitro with cell lines overexpressing UGT1A8 variants, the UGT1A8*2 variant was significantly (P = 0.023) correlated with total raloxifene glucuronide formation in human jejunum homogenates. While ral-4'-Gluc exhibited 1:100th the anti-estrogenic activity of raloxifene itself as measured by binding to the estrogen receptor, raloxifene glucuronides comprised about 99% of the circulating raloxifene dose in raloxifene-treated subjects, with ral-4'-Gluc comprising ~70% of raloxifene glucuronides. Plasma ral-6-Gluc (Ptrend = 0.0025), ral-4'-Gluc (Ptrend = 0.001), and total raloxifene glucuronides (Ptrend = 0.001) were increased in raloxifene-treated subjects who were predicted slow metabolizers [UGT1A8 (*1/*3)] versus intermediate metabolizers [UGT1A8 (*1/*1) or UGT1A8 (*1/*2)] versus fast metabolizers [UGT1A8 (*2/*2). These data suggest that raloxifene metabolism may be dependent on UGT1A8 genotype and that UGT1A8 genotype may play an important role in overall response to raloxifene. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23682072      PMCID: PMC4057281          DOI: 10.1158/1940-6207.CAPR-12-0448

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  43 in total

1.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Authors:  Daniel C Kemp; Peter W Fan; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

2.  O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

Authors:  Q Ren; S E Murphy; Z Zheng; P Lazarus
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

Review 3.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8.

Authors:  Z Cheng; A Radominska-Pandya; T R Tephly
Journal:  Arch Biochem Biophys       Date:  1998-08-15       Impact factor: 4.013

5.  Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk.

Authors:  Abul Elahi; Jean Bendaly; Zhong Zheng; Joshua E Muscat; John P Richie; Stimson P Schantz; Philip Lazarus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

6.  Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome by genotyping UGT1A1*28 promoter polymorphism.

Authors:  S K Rauchschwalbe; M T Zühlsdorf; U Schühly; J Kuhlmann
Journal:  Int J Clin Pharmacol Ther       Date:  2002-06       Impact factor: 1.366

7.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4.

Authors:  Doris Wiener; Daniel R Doerge; Jia-Long Fang; Pramod Upadhyaya; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

9.  Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant.

Authors:  Jia-Long Fang; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

10.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Authors:  P J Bosma; J R Chowdhury; C Bakker; S Gantla; A de Boer; B A Oostra; D Lindhout; G N Tytgat; P L Jansen; R P Oude Elferink
Journal:  N Engl J Med       Date:  1995-11-02       Impact factor: 91.245

View more
  12 in total

1.  Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Authors:  Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2014-01-07       Impact factor: 4.030

2.  Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats.

Authors:  Yifan Tu; Lu Wang; Yi Rong; Vincent Tam; Taijun Yin; Song Gao; Rashim Singh; Ming Hu
Journal:  Elife       Date:  2021-07-01       Impact factor: 8.140

3.  Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines.

Authors:  Douglas F Dluzen; Aimee K Sutliff; Gang Chen; Christy J W Watson; Faoud T Ishmael; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2016-07-29       Impact factor: 4.030

4.  Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Authors:  Brandon T Gufford; Gang Chen; Ana G Vergara; Philip Lazarus; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-06-12       Impact factor: 3.922

5.  Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.

Authors:  Shenghui Mei; Weixing Feng; Leting Zhu; Xingang Li; Yazhen Yu; Weili Yang; Baoqin Gao; Xiaojuan Wu; Fang Fang; Zhigang Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-04-17       Impact factor: 2.953

6.  Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids.

Authors:  Peimin Dai; Lijun Zhu; Feifei Luo; Linlin Lu; Qiang Li; Liping Wang; Ying Wang; Xinchun Wang; Ming Hu; Zhongqiu Liu
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

7.  Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.

Authors:  Brandon T Gufford; Gang Chen; Philip Lazarus; Tyler N Graf; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2014-07-09       Impact factor: 3.922

8.  Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.

Authors:  B T Gufford; J T Barr; V González-Pérez; M E Layton; J R White; N H Oberlies; M F Paine
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-28

9.  Label-free LC-MS/MS shotgun proteomics to investigate the anti-inflammatory effect of rCC16.

Authors:  Min Pang; Xin-Yan Bai; Yan Li; Ji-Zhong Bai; Li-Rong Yuan; Shou-An Ren; Xiao-Yun Hu; Xin-Ri Zhang; Bao-Feng Yu; Rui Guo; Hai-Long Wang
Journal:  Mol Med Rep       Date:  2016-10-12       Impact factor: 2.952

10.  Characterization of metabolic activity, isozyme contribution and species differences of bavachin, and identification of efflux transporters for bavachin-O-glucuronide in HeLa1A1 cells.

Authors:  Yang Li; Chunxia Xu; Jinjin Xu; Zifei Qin; Shishi Li; Liufang Hu; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Pharmacol       Date:  2020-07-09       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.